8/8/2022 8:08:07 AM
Sesen Bio Q2 Net Loss $32.0 Mln Or $0.16/shr Vs Net Loss Of $25.4 Mln Or $0.15/shr Prior Year
7/18/2022 7:38:15 AM
Sesen Bio To Pause Clinical Development Of Vicineum In US
5/9/2022 8:24:51 AM
Sesen Bio Q1 Net Loss $0.8 Mln Or $0.00/shr Vs Net Loss Of $55.5 Mln Or $0.35/shr Prior Year
5/3/2022 8:21:34 AM
Sesen Bio Initiates Process To Review Strategic Alternatives, Incl. Sale
2/28/2022 8:12:49 AM
Sesen Bio Q4 EPS $0.04 Vs. Loss/shr $0.11 Last Year
12/9/2021 8:18:00 AM
Sesen Bio Announces Regulatory Path Forward For Vicineum; Expects To Hold Type C Meeting With FDA In Early 2022
11/8/2021 8:06:50 AM
Sesen Bio Q3 EPS $0.36 Vs. Loss/shr $0.19 Last Year
11/1/2021 8:09:03 AM
Sesen Bio Announces Productive CMC Type A Meeting With The FDA
10/12/2021 8:12:41 AM
Sesen Bio Says Welcomes Eun And Chrie O Further Strengthen
capabilities Across CMC And Clinical Teams
8/9/2021 7:15:07 AM
Sesen Bio Q2 Loss/shr Narrows To $0.15 From $0.24 Last Year
8/5/2021 8:20:00 AM
Sesen Bio Announces Partnership With Eczacibasi Pharma Marketing
for Commercialization Of Vicineum In Turkey
8/2/2021 8:08:31 AM
Sesen Bio Appoints Amy Ponpipom As VP Assistant General Counsel